본문으로 건너뛰기
← 뒤로

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

2/5 보강
Cell reports. Medicine 📖 저널 OA 99.2% 2021: 1/1 OA 2024: 9/9 OA 2025: 45/46 OA 2026: 73/73 OA 2021~2026 2026 Vol.7(4) p. 102694 OA Extracellular vesicles in disease
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
68 patients, we accurately differentiate between benign lung changes and early-stage lung cancer.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings underscore the potential of sEVs as diagnostic markers for cancer screening. Furthermore, the multiplex microfluidic device's scalability, simplicity, and cost-effectiveness indicate feasibility for large-scale population screening.
OpenAlex 토픽 · Extracellular vesicles in disease Phagocytosis and Immune Regulation S100 Proteins and Annexins

Lobb RJ, Zhou Q, Fielding D, Visan KS, Wuethrich A, Wang J

📖 무료 전문 🔓 OA PDF oa
📝 환자 설명용 한 줄

Small extracellular vesicles (sEVs) offer a promising, non-invasive method for cancer detection.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Richard J. Lobb, Quan Zhou, et al. (2026). Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.. Cell reports. Medicine, 7(4), 102694. https://doi.org/10.1016/j.xcrm.2026.102694
MLA Richard J. Lobb, et al.. "Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.." Cell reports. Medicine, vol. 7, no. 4, 2026, pp. 102694.
PMID 41881025 ↗

Abstract

Small extracellular vesicles (sEVs) offer a promising, non-invasive method for cancer detection. Despite global research efforts, successful translation of sEV-based diagnostics remains limited. In this study, we identify a 4-protein sEV biomarker panel (thrombospondin-1, nidogen-1, pentraxin-3, and versican) based on proteomic profiles obtained from an isogenic cancer cell line model. The panel's performance is validated across 22 cancer cell lines and 764 retrospective plasma/serum samples spanning multiple cancer types, yielding robust performance (area under the curve [AUC]: 0.91-1.00). To facilitate clinical application, we develop a multiplex sEV device that integrates nanoshearing-based microfluidics and surface-enhanced Raman scattering (SERS) for simultaneous detection of the 4-protein panel. Using this device on a prospective cohort of 68 patients, we accurately differentiate between benign lung changes and early-stage lung cancer. These findings underscore the potential of sEVs as diagnostic markers for cancer screening. Furthermore, the multiplex microfluidic device's scalability, simplicity, and cost-effectiveness indicate feasibility for large-scale population screening.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기